论文部分内容阅读
1987年美国抗菌剂销售额超过35亿美元,其中口服剂近占1/2,尽管大多数价格昂贵的新抗生素均是注射剂如第三代头孢菌素、碳青霉烯类(Imipenem)、β-内酰胺酶抑制剂的复合制剂和单酰胺菌素(Aztreon-am)。直至约3～4年前第一个氟喹诺酮类药物氟哌酸出现以前,口服抗菌剂一直没有新的进展。目前许多新喹诺酮类如环丙氟哌酸、氟啶酸、氟嗪酸,甲氟哌酸等均可用于某些需传统药物长期注射治疗的严重感染。但是由于这些喹
In 1987, the sales volume of antibacterial agents in the United States surpassed 3.5 billion U.S. dollars, accounting for nearly 1/2 of that of oral antibiotics. Although most of the expensive new antibiotics are injections such as third generation cephalosporins, Imipenem, β -lactamase inhibitor and Aztreon-am. Until about three to four years ago, the first fluoroquinolone, norfloxacin, there had been no new progress in oral antibacterials. At present, many new quinolones such as Ciprofloxacin, Hypnuric acid, Flucloxacin, Norfloxacin, etc. can be used for some serious infections requiring traditional Chinese medicine for long-term injections. However, due to these Qui